Additional File 6.

Additional file 1: Figure S1. HPLC analysis of SMI from different batches. (A) HPLC analysis of SMI (Lot No. 1907018). (B) HPLC analysis of SMI (Lot No. 1907229). (C) HPLC analysis of SMI (Lot No. 1907277).

Additional file 3: Figure S3. BMNC count in each group. Cells were isolated on Day 10 (n = 6 for Control group, n = 3 for Model group, n = 8 for SMI group, n = 6 for S+Rg group, n = 6 for S group and n = 7 for Rg group). The results are expressed as the means ± SEM. ##p < 0.01, compared with Control group; ＊p < 0.05, ＊＊p < 0.01,...

Additional file 1: Figure S1. The gating strategies for the flow cytometry experiments. Data analysis was performed using FlowJo (Ashland, OR). Scatter and staining with the FITC-anti-CD41 and PE-anti-CD40L antibodies were used to gate platelet population. Cells were first gated by regions within a side scatter area (SSC-A) versus forward scatter area (FSC-A) plot, and then through gating those populations in the SSC-A versus FITC-A plots. Activated platelets were defined as FITC-anti-CD41-A positive and PE-anti-CD40L-A...

Additional file 7: Figure S7. Effect of LPS and CD40L on TRAFs proteins in EGCs. a Representative western blot images of TRAFs proteins expression in EGCs. b–g Western blot analysis of TRAF1 (b), TRAF2 (c), TRAF3 (d), TRAF4 (e), TRAF5 (f) and TRAF6 (g) expression in different groups of EGCs (n = 6). The data are presented as the mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Additional file 1: Figure S1. Representative typical immunohistochemical staining images of positive and negative nuclear expressions of MLH1, MSH6 and PMS2

Additional file 2: Figure S2. Kaplan-Meier estimates of overall survival (OS) in stage III dMMR patients with or without chemotherapy

Additional file 2: Figure S2. Kaplan-Meier estimates of overall survival (OS) in stage III dMMR patients with or without chemotherapy

Additional file 1: Fig. S1. Study participant flow diagram.

Additional file 7: Fig S5. TPRG1L promoted GBC cell proliferation. (A) CCK8 assay and (B) colony formation were performed to evaluated proliferation capacity after transfection with vector or TPRG1L. (C) Relative protein expression of TPRG1L, p65, p50, c-myc, CDK2, and p-CDK2 after transfection with vector or TPRG1L. (D) Representative IHC micrographs showing TPRG1L protein expression in GBC tissues with high or low miR-143-3p expression. *P < 0.05, **P < 0.01, ***P < 0.001.

Additional file 3: Supplementary Figure 3. The original and uncropped gel image of collagen III and α-SMA.

Additional file 5: Supplementary Figure 5. The original and uncropped gel image of p-P38 and GAPDH.

Additional file 1: Figure S1. RT-qPCR validation of DE protein-coding genes identified by RNA-seq. Validation of 5 upregulated and 5 downregulated protein-coding genes in atm mutated flies. Error bars indicate SEM.

Additional file 3: Figure S3. Tissue expression of differentially expressed protein-coding genes in atm mutated flies after ionizing radiation. A Heatmap of differentially expressed genes expressed in larval tissues. B Heatmap of differentially expressed genes expressed in adult female tissues. C Heatmap of differentially expressed genes expressed in adult male tissues.

Additional file 1: Figure S1. The mRNA level of CBFA1 in qRT-PCR (a) and RNA-Seq (b). *P < 0.05.

Additional file 4: Figure S4. HE (scale bar = 50 μm) and Masson (scale bar = 50 μm) staining were performed to evaluate ectopic bone formation in nude mice (n=4).

Additional file 2: Figure S2. The distribution of Panx 1 in the DRG and within sciatic nerves. A. Double-immunofluorescence images of Panx 1 (green) and the sciatic nerve axonal marker, NF200 (red). (B). Images of Panx 1 immunostaining (red) and, Nissl staining (green) in the DRG; Scale bar = 50 μm. Enlarged images in lower panel are from the inset boxes of upper panel. Upper panel, scale bar = 100 μm. Lower panel, scale bar...

Additional file 3: Figure S3. ShRNA Panx 1-AAV or Ctrl-AAV-labeled EGFP-positive cells have a sound co-localization with S100 β-labeled Schwann cells. Enlarged images in lower panel are from the inset boxes of upper panel. Upper panel, scale bar = 50 μm. Lower panel, scale bar = 25 μm. n = 3–4 mice/group.

Additional file 7: Figure S7. Cytokine array reveals Panx 1-dependent cytokines and chemokines in LPS-treated Schwann cells. A. Coordinates of the cytokine array containing 40 different cytokines and chemokines, including three positive control (PC) proteins. B. Array membranes of protein expression among Ctrl, Ctrl-siRNA, and Panx 1-siRNA groups in LPS-treated Schwann cells.

Supplemental material, sj-jpg-2-jbm-10.1177_03936155221132292 for Development and validation of a nomogram involving immunohistochemical markers for prediction of recurrence in early low-risk endometrial cancer by Wei Kong, Yuan Tu, Peng Jiang, Yuzhen Huang, Jingni Zhang, Shan Jiang, Ning Li and Rui Yuan in The International Journal of Biological Markers

Supplemental material, sj-jpg-2-jbm-10.1177_03936155221132292 for Development and validation of a nomogram involving immunohistochemical markers for prediction of recurrence in early low-risk endometrial cancer by Wei Kong, Yuan Tu, Peng Jiang, Yuzhen Huang, Jingni Zhang, Shan Jiang, Ning Li and Rui Yuan in The International Journal of Biological Markers

Additional file 3: Figure S1. ROC curves for 5-year survival of IPI and predictive factors significant in univariate analysis. A, ROC curves for 5-year OS of IPI and predictive factors significant in univariate analysis. B, ROC curves for 5-year PFS of IPI and predictive factors significant in univariate analysis.

Additional file 4: Figure S2. Kaplan–Meier survival curves of patients with PBL treated with RCHOP and CHOP categorized by IPI scores. A, Kaplan–Meier survival curves for OS of patients treated with RCHOP. B, Kaplan–Meier survival curves for PFS of patients treated with RCHOP. C, Kaplan–Meier survival curves for OS of patients treated with CHOP. D, Kaplan–Meier survival curves for PFS of patients treated with CHOP.

Additional file 4: Figure S2. Kaplan–Meier survival curves of patients with PBL treated with RCHOP and CHOP categorized by IPI scores. A, Kaplan–Meier survival curves for OS of patients treated with RCHOP. B, Kaplan–Meier survival curves for PFS of patients treated with RCHOP. C, Kaplan–Meier survival curves for OS of patients treated with CHOP. D, Kaplan–Meier survival curves for PFS of patients treated with CHOP.

Additional file 5: Figure S3. Literature screening flow chart.